Article

An ultrapotent neutralizing bispecific antibody with broad spectrum against SARS-CoV-2 variants

2021-08-10

Abstract excerpt

In spite of the successful development of effective countermeasures against Covid-19, variants have and will continue to emerge that could compromise the efficacy of currently approved neutralizing antibodies and vaccines. Consequently, novel and more efficacious agents are urgently needed. We have developed a bispecific antibody, 2022, consisting of two antibodies, 2F8 and VHH18. 2F8 was isolated from our proprie...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: e2a57529-215f-50a8-8778-2e58a2f5e42c
DOI: 10.1101/2021.08.10.455627

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

An ultrapotent neutralizing bispecific antibody with broad spectrum against SARS-CoV-2 variantsDOI 10.1101/2021.08.10.455627Read

An Ultrapotent Neutralizing Bispecific Antibody with Broad Spectrum Against SARS-CoV-2 VariantsSemantic proximity Read

Ultrapotent bispecific antibodies neutralize emerging SARS-CoV-2 variantsSemantic proximity Read

Dual Epitope Engagement Enables Broad-Spectrum Neutralization of SARS-CoV-2 Variants by Bispecific Antibody 9A6-6C3Semantic proximity Read

Novel bispecific human antibody platform specifically targeting a fully open spike conformation potently neutralizes multiple SARS-CoV-2 variantsSemantic proximity Read

Antibody drugs targeting SARS-CoV-2: Time for a rethink?Semantic proximity Read

An ultrapotent RBD-targeted biparatopic nanobody neutralizes broad SARS-CoV-2 variantsSemantic proximity Read

Ultrapotent SARS-CoV-2 neutralizing antibodies with protective efficacy against newly emerged mutational variantsSemantic proximity Read

An ultrapotent RBD-targeted biparatopic nanobody neutralizes broad SARS-CoV-2 variantsSemantic proximity Read

A novel bispecific antibody dual-targeting approach for enhanced neutralization against fast-evolving SARS-CoV-2 variantsSemantic proximity Read

MTX-COVAB, a human-derived antibody with potent neutralizing activity against SARS-CoV-2 infection <i>in vitro</i> and in a hamster model of COVID-19Semantic proximity Read

Cross-neutralization antibodies against SARS-CoV-2 and RBD mutations from convalescent patient antibody librariesSemantic proximity Read

Bispecific antibodies targeting the N-terminal and receptor binding domains potently neutralize SARS-CoV-2 variants of concernSemantic proximity Read